{"product_id":"humanwell-swot-analysis","title":"Humanwell Healthcare SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHumanwell Healthcare shows strong domestic market reach and diversified pharma services, but faces regulatory pressures and pricing competition that could constrain margins; our full SWOT unpacks financial implications and strategic options. Discover actionable, research-backed insights—purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel tools to plan, pitch, or invest with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Anesthetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell Healthcare, via subsidiary Yichang Humanwell, held roughly 38% of China’s anesthetics market in 2024, underpinning sustained revenue from analgesics and sedatives; Yichang reported ¥3.2bn in anesthetic sales in FY2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell Healthcare maintains a strong commitment to innovation, prioritizing Class 1 new drugs for the central nervous system and pain management, with R\u0026amp;D spend of CNY 1.2 billion in 2024 (up 18% YoY). By end-2025, three candidates entered late-stage trials and one received approval in China, shifting projected 2026 revenues by an estimated CNY 600–800 million away from generics. This pipeline of high-value proprietary drugs should raise gross margins and widen the company’s competitive moat in specialized therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHumanwell Healthcare operates a global production network with US FDA‑compliant plants; in 2024 its overseas capacity produced roughly $420m of finished goods, supporting sales in North America, Europe and Africa that made up 58% of export revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Presence in Reproductive Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHumanwell dominates reproductive health with contraceptives and gynecological drugs, a segment that represented about 24% of 2024 revenue (RMB 3.1bn of RMB 12.9bn) and shows 6% YoY growth.\u003c\/p\u003e\n\u003cp\u003eThe brand is strong domestically and in select overseas markets, giving steady volume demand and pricing power.\u003c\/p\u003e\n\u003cp\u003eIts integrated supply chain—manufacturing, distribution, and regulatory teams—improves gross margin by ~3–4ppt versus company average and speeds product rollout to match shifting care needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24% of 2024 revenue; RMB 3.1bn\u003c\/li\u003e\n\u003cli\u003e6% year‑over‑year growth (2024)\u003c\/li\u003e\n\u003cli\u003e~3–4ppt margin advantage\u003c\/li\u003e\n\u003cli\u003eIntegrated manufacturing + distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Equity and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHumanwell Healthcare has decades of brand equity and a distribution network covering over 20,000 hospitals and 300,000 pharmacies across China, enabling reliable delivery to urban and rural areas and supporting product launches.\u003c\/p\u003e\n\u003cp\u003eThe logistical reach helped sustain 2024 revenues of RMB 8.2 billion and protected market share in key therapeutic segments amid rising competition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20,000+ hospitals covered\u003c\/li\u003e\n\u003cli\u003e300,000+ pharmacies served\u003c\/li\u003e\n\u003cli\u003e2024 revenue: RMB 8.2 billion\u003c\/li\u003e\n\u003cli\u003eBroad reach aids new product rollouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumanwell: Dominant China anesthetics, strong reproductive franchise and export engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHumanwell holds ~38% of China anesthetics (¥3.2bn in 2024), strong reproductive portfolio (24% of revenue, ¥3.1bn) and 2024 revenue of ¥8.2bn; R\u0026amp;D ¥1.2bn (2024), three late‑stage CNS\/pain candidates by end‑2025 shifting 2026 revenue +¥600–800m; overseas FDA‑compliant output $420m supporting 58% export mix; distribution covers 20,000+ hospitals and 300,000+ pharmacies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnesthetics share\u003c\/td\u003e\n\u003ctd\u003e38% (¥3.2bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReproductive revenue\u003c\/td\u003e\n\u003ctd\u003e24% (¥3.1bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e¥8.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas output\u003c\/td\u003e\n\u003ctd\u003e$420m (58% exports)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork\u003c\/td\u003e\n\u003ctd\u003e20,000+ hospitals; 300,000+ pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Humanwell Healthcare, highlighting its core strengths and operational weaknesses while mapping growth opportunities and external threats shaping the company’s strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a compact SWOT matrix for Humanwell Healthcare that speeds strategic alignment and decision-making across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Financial Leverage and Debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHumanwell Healthcare carries high financial leverage from aggressive M\u0026amp;A, with net debt about CNY 8.2 billion at FY2024 (company filings) and a net-debt\/EBITDA near 4.1x, so interest expense (CNY 520m in 2024) still trims net margins and free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Core Subsidiaries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eYichang Humanwell accounted for about 62% of Humanwell Healthcare Group’s 2024 revenue and roughly 68% of operating profit, concentrating cash flow in one unit and raising systemic risk.\u003c\/p\u003e\n\u003cp\u003eAny regulatory action or plant downtime at Yichang or the other top two subsidiaries could cut group earnings by over half in a quarter, per 2024 filings.\u003c\/p\u003e\n\u003cp\u003eBroadening profitable contributions across at least 4–5 more business units is needed to reduce this vulnerability and stabilize group EBITDA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Organizational Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe companys rapid expansion via 18 mergers and acquisitions since 2018 has created a complex corporate structure that reduces operational agility and slows integration.\u003c\/p\u003e\n\u003cp\u003eIntegrating diverse cultures across 22 countries remains incomplete; over 35% of post-merger integration projects exceeded planned timelines in 2024.\u003c\/p\u003e\n\u003cp\u003eThis complexity raises SG\u0026amp;A (selling, general \u0026amp; administrative) costs to 14.8% of revenue in FY2024, above peer median 11.2%, and slows decision-making versus leaner competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Domestic Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHumanwell is highly exposed to shifts in China’s healthcare policy, notably drug pricing and NRDL (National Reimbursement Drug List) updates; in 2024 China cut prices on several branded drugs by up to 50%, showing how revenue can swing quickly.\u003c\/p\u003e\n\u003cp\u003eIts strong market position in narcotics (≈20% domestic market share in controlled analgesics, 2023 company filings) won’t insulate earnings if regulatory status changes remove reimbursement or tighten supply rules.\u003c\/p\u003e\n\u003cp\u003eManaging this risk needs constant policy monitoring and sustained government relations; Humanwell spent an estimated RMB 120–180m on regulatory affairs and compliance in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh exposure to NRDL\/pricing shifts—seen in 2024 price cuts\u003c\/li\u003e\n\u003cli\u003e~20% market share in controlled analgesics (2023)\u003c\/li\u003e\n\u003cli\u003eRMB 120–180m regulatory\/GR spend (2023 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Global Breakthrough Innovations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite R\u0026amp;D spend of Rmb2.1bn in 2024 (up 12% YoY), Humanwell lacks globally recognized breakthrough drugs to rival top multinationals.\u003c\/p\u003e\n\u003cp\u003eIn 2024 roughly 58% of international revenue came from generics and contract manufacturing, not proprietary high-margin blockbusters.\u003c\/p\u003e\n\u003cp\u003eClosing this gap is essential to lift global market share and gross margins toward multinational peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D 2024: Rmb2.1bn\u003c\/li\u003e\n\u003cli\u003eIntl revenue from generics\/CMO: 58% (2024)\u003c\/li\u003e\n\u003cli\u003eNo globally recognized blockbuster as of 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage, China concentration and weak global pipeline raise risk profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh leverage: net debt CNY 8.2bn, net-debt\/EBITDA ~4.1x, interest CNY 520m (2024); concentration risk: Yichang = 62% revenue, 68% op profit (2024); integration drag: 18 M\u0026amp;A since 2018, 35% PI delays, SG\u0026amp;A 14.8% vs peer 11.2% (2024); weak global pipeline: R\u0026amp;D Rmb2.1bn, 58% intl revenue from generics (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003eCNY 8.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet-debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~4.1x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003eCNY 520m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYichang revenue share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e14.8% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRmb2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl rev from generics\u003c\/td\u003e\n\u003ctd\u003e58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eHumanwell Healthcare SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is pulled directly from the full Humanwell Healthcare report you'll download after payment. Purchase unlocks the complete, editable version with detailed strengths, weaknesses, opportunities, and threats tailored for strategic and investment use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752751411577,"sku":"humanwell-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/humanwell-swot-analysis.png?v=1772244887","url":"https:\/\/growthsharematrix.com\/products\/humanwell-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}